Lactobacillus salivarius – LS01 (DSM 22775)

FUNCTIONALITY
Immunomodulatory activity in asthmatic subjects

Clinical study on-going on asthma

+ Internal data available on the immunomodulation capacities of the strains

DAILY DOSAGE IN CLINICAL STUDY
1,2,3) 2 billion CFU
4) 5 billion CFU + 2 billion CFU of Streptococcus thermophilus ST10 + Tara gum

FUNCTIONALITY
Treatment of atopic dermatitis • Improvement of the Quality of Life in subjects with Atopic Dermatitis • Skin health • Inhibition of C. acnes (formerly classified as P. acnes)–induced IL-8 release

Human clinical trials
1) Drago L. et al. Effects of Lactobacillus salivarius LS01 (DSM 22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study. Int J Immunopathol Pharmacol. 2011; 24(4):1037-48.
2) Drago L. et al. Changing of fecal flora and clinical effect of L. salivarius LS01 in adults with atopic dermatitis. J Clin Gastroenterol. 2012; 46 Suppl:S56-63.
3) Niccoli A. et al. Preliminary results on clinical effects of probiotic Lactobacillus salivarius LS01 in children affected by atopic dermatitis. J Clin Gastroenterol. 2014; 48 Suppl:S34-36.
4) Drago L. et al. Treatment of atopic dermatitis eczema with a high concentration of Lactobacillus salivarius LS01 associated with an innovative gelling complex. J Clin Gastroenterol. 2014; 48 Suppl:S47-511.

In vitro study
a) Drago L. et al. Strain-dependent release of cytokines modulated by Lactobacillus salivarius human isolates in an in vitro model. BMC Res Notes. 2010; 3:44.
b) Deidda F. et al. New Approach in Acne Therapy, A Specific Bacteriocin Activity and a Targeted Anti IL-8 Property in Just 1 Probiotic Strain, the L. salivarius LS03. (LS01, LS02, LS03) J Clin Gastroenterol 2018;52:S78-S81.

DAILY DOSAGE IN CLINICAL STUDY
1,3,4) 2 billion CFU + 2 billion CFU LS01 + BR03
2) 1 billion CFU + 1 billion CFU

FUNCTIONALITY
Reduce frequency, duration and intensity of Atopic Dermatitis symptoms • Improvement of the Quality of Life in subjects with Atopic Dermatitis (AD) • Rosacea • Chronic urticaria • Skin health

Human clinical trials
1) Iemoli E. et al. Probiotics reduce gut microbial translocation and improve adult atopic dermatitis. J Clin Gastroenterol. 2012; 46 Suppl:S33-40.
2) Licari A. et al. Efficacia clinica di Lactobacillus salivarius LS01 e Bifidobacterium breve BR03 in pazienti pediatrici affetti da dermatite atopica. Il medico pediatra 2016;38-42.
3) Nettis E. et al. Probiotics and refractory chronic spontaneous urticaria. Eur Ann Allergy Immunol 2016, Vol 48, N 5, 182-187.
4) Fortuna M. C. et al. A case of Scalp Rosacea treated with low dose doxycycline and probiotic therapy and literature review on therapeutic options. Dermatologic Therapy ISSN 1396-0296; DOI:10.1111/12355.

+ Refer to precedent page for additional studies on LS01 alone in atopic dermatitis

In vitro study
a) Deidda F. et al. New Approach in Acne Therapy: A Specific Bacteriocin Activity and a Targeted Anti IL-8 Property in Just 1 Probiotic Strain, the L. salivarius LS03. J Clin Gastroenterol. 2018 May 18.
b) Drago L. Immunomodulatory Effects of Lactobacillus salivarius LS01 and Bifidobacterium breve BR03, alone and in combination, on Peripheral Blood Mononuclear Cells of Allergic Asthmatics. Allergy Asthma Immunol Res. 2015 July; 7(4):409-413.

FUNCTIONALITY
Antioxidant activity • Reduced glutathione (GSH) and superoxide dismutase (SOD) production

Internal in vitro data available upon request on above-mentioned functions and strains

In vitro study publication pending

Poster available upon request: on oxidative stress, membrane permeability and cytokine modulation with implications in Parkinson’s Disease.

Further evidence on immunomodulation properties and anti-oxidant activity of these strains is available upon request